Targets › RPLC
2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on RPLC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Huashan Hospital | Linezolid Bacterial 70S ribosome inhibitor | RPLC | Phase 3 | Multidrug Resistant Tuberculosis; Drug-resistant Tuberculosis | Dec 2026 |
| The Aurum Institute NPC | Sutezolid Oxazolidinone antibiotic; inhibits bacterial protein synthesis by binding to the 50S ribos | RPLC | Phase 2 | Tuberculosis | – |
Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Tuberculosis (1)
small molecule (1)
Huashan Hospital (1) The Aurum Institute NPC (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.